¿Qué hemos aprendido en estos dos años del manejo del paciente con Cáncer de Pulmón No Microcítico en segunda línea de tratamiento con Inmunoterapia?

Lu S. et al. CSCO 2017

Treatment-Related Select AEsa in

Nivolumab-Treated Patients

(Checkmate 017 and 057 3-Year Update; Pooled Analysis)

Nivolumab

(N = 418)

Any grade

Grade 3−4

Overall, %

37.1

4.8

Skin

16.3

1.0

Gastrointestinal

9.1

1.2

Endocrine

8.6

Hepatic

5.7

1.0

Pulmonary

4.5

1.4

Renal

2.6

0.2

Hypersensitivity/infusion reaction

2.4

Select AEs are those with potential immunologic etiology that require frequent monitoring/intervention

Includes events reported between first nivolumab dose and 30 days after last nivolumab dose